Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

By sjmartinez • April 19, 2024

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024 Apr 17;190(5):668-679. doi: 10.1093/bjd/ljae014. PMID: 38226713.

Tags: Dermatology, Olive View DoM, Publications

Measles Resurgence: What Every Dermatologist Should Know

Freeman E, Li C, Castillo D, Ahuja S, Chiu YE, Elewski B, Goh C, Hu J, Rosmarin D, Trinidad J, Rosenbach M. Measles Resurgence: What[...]

Collagen V regulates renal function after kidney injury and can be pharmacologically targeted to enhance kidney repair in mice

Su L, Sun Q, Li Y, Alvarez JF, Tao B, Zhang G, Gu Y, Hanudel MR, Espinoza A, Zhang L, Pan C, Hilser JR, Hartiala[...]

Genome-wide DNA methylation patterns in Daphnia magna are not significantly associated with age

Liu R, Morselli M, Yampolsky LY, Peshkin L, Pellegrini M. Genome-wide DNA methylation patterns in Daphnia magna are not significantly associated with age. Epigenetics Chromatin.[...]